Cidara Therapeutics   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Diego CA United States (2012)

Organization Overview

First Clinical Trial
2015
NCT02516904
First Marketed Drug
2023
rezafungin (REZZAYO)
First NDA Approval
2023
rezafungin (REZZAYO)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cidara Therapeutics Inc. | CIDARA THERAPS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidemia (Phase 3)

Candidiasis (Phase 3)

Candidiasis, Invasive (Phase 3)

Candidiasis, Vulvovaginal (Phase 2)

Communicable Diseases (Phase 3)

Fungemia (Phase 3)

Infections (Phase 3)

Invasive Fungal Infections (Phase 3)

Mycoses (Phase 3)

Pneumonia, Pneumocystis (Phase 3)

Vaginitis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8